Platelet Rich Plasma Market Expected to Reach at CAGR of 14% up to 2023 - BIO PRODUCT LABORATORY, BIOLIFE PLASMA SERVICES, BIOTEST, CAMBRYN BIOLOGICS, CHINA BIOLOGIC PRODUCTS, CSL, GRIFOLS INTERNATIONAL S.A

The platelet-rich plasma market is expected to grow at a CAGR of 14% during the forecast period. Platelet-rich plasma (PRP) prolotherapy, like dextrose prolotherapy, is a method of injection designed to stimulate healing. Platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels, which contains at least seven growth factors.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/17123

Prevalence of Arthritis
Osteoarthritis (OA) is the most common form of chronic disorder of the joints, and it has some detrimental effects on the quality of life of the patients. Progressive cartilage destruction, osteophyte formation, and subchondral sclerosis are characteristic to osteoarthritis. Platelet-rich plasma (PRP) is an autologous concentration of a high number of platelets in a small volume of plasma. PRP is prepared centrifuging blood. In knee OA, PRP injections target to promote cartilage repair in order to relieve symptoms of osteoarthritis, hence delaying the need for joint replacement surgery. This will help boost the growth of this market in the forecast period. Along with this, other factors, such as rising incidences of sports injuries, increase in the number of androgenic alopecia patients, and growing use of platelet-rich plasma in various therapeutic areas will also lead to the growth of the market.

Key Developments in the Market:
November 2017 - The Cascade Medical’s FIBRINETu00ae System designed to be used for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care received FDA approval in the United States.

Major Players:
BIO PRODUCT LABORATORY LTD (BPL), BIOLIFE PLASMA SERVICES, BIOTEST, CAMBRYN BIOLOGICS LLC, CHINA BIOLOGIC PRODUCTS, INC., CSL LTD, GRIFOLS INTERNATIONAL S.A., KEDRION S.P.A., LFB SA, AND OCTAPHARMA, amongst others.

Request Discount on this report @ https://marketprognosis.com/discount-request/17123

High Prices of Plasma Therapy
Plasma-rich platelet therapy, being a relatively new procedure, is generally expensive to undergo. Therefore, patients who have the symptoms might require plasma-rich platelet therapy. Also, as insurance companies consider platelet-rich plasma therapy as an experimental treatment, it is also not covered by them and leads to out-of-pocket expenses, which ends up being costly for the patients. This, along with other factors, such as stringent regulatory policies, will lead to the slowdown of the growth of the market.

North America to Maintain Lead in the Market
North America is expected to dominate the market, followed by Europe. Asia-Pacific is expected to grow at the highest CAGR during the forecast period. This can be attributed to the rising number of osteoarthritis and sports injury cases in this region in the APAC region. The increasing focus of prominent players on APAC is also supporting market growth in the region.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/17123

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.